Pharming Group Q3 2026 Earnings Date & Estimates

Pharming Group (NASDAQ:PHAR) N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder. The company also maintains a pipeline focused on additional rare and specialty diseases.

Founded in 1988, Pharming serves patients and healthcare providers in the United States, Europe and other international markets through its own commercial operations and regional partnerships. Its shares trade on Euronext Amsterdam and, through American depositary shares, on the Nasdaq under the symbol PHAR.